Evidence map›Paper›PMID 25666029›Full record

ArticleEuropean journal of clinical pharmacology2015

Drug-target based cross-sectional analysis of olfactory drug effects.

Jörn Lötsch, Helena Daiker, Antje Hähner, Alfred Ultsch, Thomas Hummel

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03775096 phase2active not recruitingnot on this mapstarted 2019, after this paper: background citation

The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease

TypeinterventionalSponsorMichele Tagliati, MDRan2019 to 2026Enrolled15ConditionsREM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson DiseaseArmsCarvedilol
NCT05109364 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation

The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study

TypeinterventionalSponsorCedars-Sinai Medical CenterRan2022 to 2026Enrolled15ConditionsSymptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's DiseaseArmsTerazosin therapy
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 25 citations in OpenAlex.

  1. Observational
  2. Olfactory Function and Olfactory Disorders.Laryngo- rhino- otologie · 2023
    Article
  3. International consensus statement on allergy and rhinology: Olfaction.International forum of allergy & rhinology · 2022
    Review
  4. Article
  5. Predictors of Olfactory Decline in Aging: A Longitudinal Population-Based Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2020
    Article
  6. Review
  7. Influence of medications on taste and smell.World journal of otorhinolaryngology - head and neck surgery · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jörn LötschInstitute of Clinical Pharmacology, Goethe-University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany, j.loetsch@em.uni-frankfurt.de.
Helena Daiker
Antje Hähner
Alfred Ultsch
Thomas Hummel
TU Dresden · DEGoethe University Frankfurt · DEPhilipps University of Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug effects on the human sense of smell attract increasing interest, yet systematic evidence from controlled studies is sparse. The present cross-sectional approach to olfactory drug effects made use of the recent developments in informatics, knowledge discovery, and data mining allowing connecting drug-related information from humans with underlying molecular drug targets.

methodsIn this prospective cross-sectional study, n = 1008 outpatients at a general practitioner were enrolled. All currently taken medications were obtained, and olfactory function was assessed by means of a clinically established 12-item odor identification test. The association between the patients' sense of smell and the administered medications was based (i) on the active pharmacological substances and (ii) on the molecular targets queried from the publicly accessible DrugBank database.

resultsOf the 168 different substances, six were taken sufficiently often to be analyzed. The administration of levothyroxine was associated with a higher olfactory score (p = 0.033). For the 168 drugs, 323 different targets could be queried. Thirty-one gene products were addressed sufficiently often to be analyzed. Besides agonistic targeting of thyroid hormone receptors (genes THRA1, THRB1) agreeing with the above result, antagonistically targeting the adrenoceptor alpha 1A (gene ADRA1A) by several unrelated medications was associated with a significantly higher olfactory score (p = 0.012).

conclusionsThe identified drug effects on olfaction are both biologically plausible based on supportive information from basic science studies. The novel molecular target-based approach suggested clear advantages over the classical drug or drug class-based approach. It increased the analyzable data volume fivefold and provided plausible hypotheses about mechanistic drug effects opening possibilities for drug discovery and repurposing.

Indexed as

AdolescentAdrenergic alpha-1 Receptor AgonistsAdultAgedAged, 80 and overCross-Sectional StudiesDrug Delivery SystemsDrug DiscoveryFemaleHumansMaleMiddle AgedOdorantsProspective StudiesReceptors, Adrenergic, alpha-1Receptors, Thyroid HormoneAdrenergic alpha-1 Receptor AgonistsReceptors, Adrenergic, alpha-1Receptors, Thyroid HormoneThyroxine

Identifiers

PMID25666029
OpenAlexW2059616684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.